Search

Your search keyword '"Faroux, Roger"' showing total 226 results

Search Constraints

Start Over You searched for: Author "Faroux, Roger" Remove constraint Author: "Faroux, Roger"
226 results on '"Faroux, Roger"'

Search Results

51. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

52. Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies.

53. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

54. PRODIGE 34-FFCD 1402-ADAGE Adjuvant chemotherapy in elderly patients ă with resected stage III colon cancer: A randomized phase 3 trial

55. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial

56. PRODIGE 34 ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer—A randomized phase III trial.

57. A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).

58. Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).

59. In reply

60. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

61. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach

62. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification

63. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer

64. Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

65. Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials.

66. REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

67. Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

68. DPYDGenotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer

69. EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

70. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

71. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

72. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial

73. PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.

74. DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.

75. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 – FFCD 0802)

77. Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old?

78. Microscopic Colitis or Functional Bowel Disease With Diarrhea: A French Prospective Multicenter Study

79. Multivariate prospective pharmacogenetic analysis in patients with resectable metastatic colorectal cancer (mCRC) receiving FOLFOX chemotherapy.

80. FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas.

81. FOLFIRI-cetuximab: A multicenter phase II proof-of-concept study of a tailored triple combination therapy for safe dose intensification.

82. Tu1178 Drugs-Induced Microscopic Colitis (MC): A French Prospective Multicenter Study

83. Tu1177 Autoimmune Disease Associated With Microscopic Colitis (MC): A French Prospective Multicenter Study

84. Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308

85. Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer.

86. 5FU/LV with or without irinotecan in patients with resected stage II-III rectal cancer: Final analysis of R98 intergroup study.

87. Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

88. Su1255 Microscopic Colitis (MC) or Irritable Bowel Syndrom (IBS) With Diarrhea: A Prospective Multicenter Study

89. Prevention of 5-FU-induced toxicities using pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

90. Efficacy and safety of FOLFIRINOX in patients with pancreatic metastatic cancer.

91. O-0019 Severe Fluoropyrimidines Toxicities: A Simple and Effective Way to Avoid Them. Screen Effectively for DPD Deficiencies.

92. Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patients

93. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting

94. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

96. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study

98. Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study

99. T1039 Lower Gastrointestinal Bleeding in General Population: Preleminary Results of a French Prospective Study Including More Than 1000 Patients

100. The Thorough Screening of the MUTYH Gene in a Large French Cohort of Sporadic Colorectal Cancers

Catalog

Books, media, physical & digital resources